Regenerative Medical Technology Group Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Regenerative Medical Technology Group Inc. (RMTG) operates as a regenerative medicine company through its strategically aligned network, offering a comprehensive suite of stem cell–based therapies, related equipment, training, and clinical infrastructure. The group focuses on providing standardized regenerative medicine treatments, physician education, and turnkey platforms for clinics and laboratories, positioning itself across a multi-country footprint. Main products and services - Regenerative medicine treatments: standardized stem cell–based therapies addressing musculoskeletal disorders, autoimmune conditions, aesthetic applications, and anti-aging indications; related biologics and cell-based products intended for physician use. - Clinical equipment and supplies: state-of-the-art laboratory and clinic equipment, processing kits, and consumables required for stem cell applications and regenerative procedures. - Training and certification: certified training courses and ongoing education for physicians and clinical staff in regenerative medicine techniques, protocols, and safety practices. - Research and development: investment in and collaboration on clinical protocols, treatment methodologies, and product improvements to enhance efficacy and safety of regenerative therapies. - Practitioner network and services: administration of a network for regenerative medicine practitioners, including standards, credentialing support, and collaborative opportunities; partnerships to expand geographic reach. - Clinic and lab deployment: development and operation of regenerative medicine clinics and accredited facilities, along with turnkey stem cell processing centers and associated support services. - Distribution and partnerships: international distribution of regenerative products, equipment, and services through affiliated channels and alliances, including alliances with relevant professional societies and educational bodies. Latest major company changes - International clinic expansion: launches of new clinics across multiple regions, expanding regional hubs for treatments and physician training; ongoing network growth in Southeast Asia and other strategic markets. - Geographic and distribution growth: expansion of distribution channels and service footprints in South America and other emerging markets to support broader access to regenerative therapies and equipment. - Strategic partnerships and affiliations: formation of alliances to create or strengthen practitioner networks and training programs, expanding the reach of IS SCA-aligned physician education initiatives and standardized treatment protocols. - Product and service launches: introduction of enhanced clinical protocols, updated training curricula, and new equipment lines designed to support scalable stem cell therapies and safer clinical practice. - Corporate or organizational adjustments: ongoing optimization of regional operations and clinic networks to improve efficiency, regulatory compliance, and patient access; potential alignment with international regenerative medicine standards through allied programs. Additional context - Industry and segments: regenerative medicine, stem cell therapy, biologics, medical training, and clinical infrastructure; includes device and supply manufacturing and distribution within the ecosystem. - Target markets: practicing physicians and clinics offering regenerative therapies; patients seeking regenerative treatments; academic and clinical partners for R&D collaboration. - Geographic operations: multi-country footprint with active clinics and distribution in Southeast Asia, South America, and other regions; focus on establishing regional hubs and local regulatory alignment. - Founding year and headquarters: established in the early 2020s; headquarters located in Frankfurt am Main, Germany, with operations and clinics managed across multiple international jurisdictions. - Subsidiaries and parent relationships: operates through affiliated networks and partnerships, with strategic affiliations to professional societies and education alliances to bolster clinician training and standardized practice.
RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin America
RMTG Launches ISSCA AI(TM) Clinical Intelligence Platform, Extending Its Global Regenerative Medicine Network Into AI-Driven Clinical Infrastructure
Global Stem Cells Group (OTC:RMTG) Launches ISSCA Mobile App, Advancing Its Buildout of a Global Digital Ecosystem for Regenerative Medicine
RMTG Subsidiary Cellgenic Commences Full-Scale Manufacturing at First-of-Its-Kind
RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit
RMTG Subsidiary CELLGENIC Expands into Dominican Republic with New Distribution Partnership
RMTG Expands into Brazil with Strategic Representation Agreement
RMTG's ISSCA Regenerative Medicine Global Summit 2025 Concludes in Cancún with Full Attendance from 30+ Countries
RMTG Partners with BKFC as Official Regenerative Medicine Provider
RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit
RMTG Expands to Puerto Rico with New Affiliate Partnership
Regenerative Medical Technologies Group Increases Q1 2025 Sales By 67% Over Q1 2024 and Achieves Operating Profit for the Quarter of $134,000
Meso Numismatics Changes Name to Regenerative Medical Technology Group and Ticker Symbol to RMTG
Meso Numismatics Announces Cellgenic's Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September
Meso Numismatics, a Renowned Leader in Regenerative Medical, Announces Global Stem Cells Groups (GSCG) Launch of Revolutionary New Line of Peptides
Meso Numismatics Announces Intention to Undergo Name Change and Authorized Shares Change
Meso Numismatics Increases 2023 Sales By 50% Year Over Year and Announces 2024 Forecast and Outlook
Meso Numismatics Closes Global Stem Cell Group Acquisition
Meso Numismatics and Global Stem Cell Group Enter Final Definitive Agreement
Meso Numismatics Announces Final Post Closing Agreement